276 related articles for article (PubMed ID: 28318337)
21. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Makin C; Lahoz R; Agashivala N; Pradhan A; Capkun G; Petrilla A; Karkare SU; Balderston McGuiness C; Korn JR
Curr Med Res Opin; 2013 Dec; 29(12):1647-56. PubMed ID: 24059944
[TBL] [Abstract][Full Text] [Related]
22. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
[TBL] [Abstract][Full Text] [Related]
23. Multiple sclerosis disease-modifying drug use by immigrants: a real-world study.
Graf J; Ng HS; Zhu F; Zhao Y; Wijnands JMA; Evans C; Fisk JD; Marrie RA; Tremlett H
Sci Rep; 2023 Dec; 13(1):21235. PubMed ID: 38040796
[TBL] [Abstract][Full Text] [Related]
24. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans.
Ozminkowski RJ; Marder WD; Hawkins K; Wang S; Stallings SC; Finkelstein SN; Sinskey AJ; Wierz D
Clin Ther; 2004 Aug; 26(8):1341-54. PubMed ID: 15476915
[TBL] [Abstract][Full Text] [Related]
25. The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil.
Maia Diniz I; Guerra AA; Lovato Pires de Lemos L; Souza KM; Godman B; Bennie M; Wettermark B; de Assis Acurcio F; Alvares J; Gurgel Andrade EI; Leal Cherchiglia M; de Araújo VE
PLoS One; 2018; 13(6):e0199446. PubMed ID: 29928006
[TBL] [Abstract][Full Text] [Related]
26. Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS.
Horakova D; Rockova P; Jircikova J; Dolezal T; Vachova M; Hradilek P; Valis M; Sucha J; Martinkova A; Ampapa R; Grunermelova M; Stetkarova I; Stourac P; Mares J; Dufek M; Kmetova E; Adamkova J; Hrnciarova T
Mult Scler Relat Disord; 2019 Oct; 35():196-202. PubMed ID: 31400559
[TBL] [Abstract][Full Text] [Related]
27. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
[TBL] [Abstract][Full Text] [Related]
28. Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.
Ng HS; Zhu F; Kingwell E; Yao S; Ekuma O; Evans C; Fisk JD; Marrie RA; Zhao Y; Tremlett H
Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35701187
[TBL] [Abstract][Full Text] [Related]
29. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis.
Hersh CM; Brook RA; Beren IA; Rohrbacker NJ; Lebson L; Henke C; Phillips AL
J Med Econ; 2021; 24(1):479-486. PubMed ID: 33739915
[TBL] [Abstract][Full Text] [Related]
30. Intracerebral Hemorrhage in Multiple Sclerosis: A Retrospective Cohort Study.
Zulfiqar M; Qeadan F; Ikram A; Farooqui M; Richardson SP; Calder CS; Quadri SA; Mathur P; Ford C; O Gutierrez S; Liera E; Snow H; N Gonzalez J; Zafar A
J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):267-275. PubMed ID: 30385221
[TBL] [Abstract][Full Text] [Related]
31. Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.
Ng HS; Graf J; Zhu F; Kingwell E; Aktas O; Albrecht P; Hartung HP; Meuth SG; Evans C; Fisk JD; Marrie RA; Zhao Y; Tremlett H
Front Immunol; 2021; 12():794075. PubMed ID: 35095869
[TBL] [Abstract][Full Text] [Related]
32. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
33. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
35. Assessment of time to follow-up visits in newly-treated hypertensive patients using an electronic medical record database.
Brixner DI; McAdam-Marx C; Ye X; Lau H; Munger MA
Curr Med Res Opin; 2010 Aug; 26(8):1881-91. PubMed ID: 20528221
[TBL] [Abstract][Full Text] [Related]
36. Early recognition of multiple sclerosis using natural language processing of the electronic health record.
Chase HS; Mitrani LR; Lu GG; Fulgieri DJ
BMC Med Inform Decis Mak; 2017 Feb; 17(1):24. PubMed ID: 28241760
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.
Munsell M; Frean M; Menzin J; Phillips AL
Patient Prefer Adherence; 2017; 11():55-62. PubMed ID: 28115831
[TBL] [Abstract][Full Text] [Related]
38. Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.
Jelinek GA; Weiland TJ; Hadgkiss EJ; Marck CH; Pereira N; van der Meer DM
Neurol Res; 2015 Aug; 37(8):662-73. PubMed ID: 25905471
[TBL] [Abstract][Full Text] [Related]
39. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Johnson BH; Bonafede MM; Watson C
CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
[TBL] [Abstract][Full Text] [Related]
40. Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.
Faught E; Laliberté F; Wang Z; Barghout V; Haider B; Lejeune D; Germain G; Choi J; Wagh A; Duh MS
Epilepsia; 2017 Oct; 58(10):1742-1748. PubMed ID: 28741690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
